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Received 31 July 2007; accepted 13 August 2007Abstract The notion that integration of cutting-edge technologies in stem cell research would be enhanced by proteomic
analyses has emanated from rapid advances in proteome technology. These advances have increased the probability that basic
properties of stem cells will be elucidated more effectively, leading to acceleration toward novel stem cell therapies. We have
therefore sought to establish a world-wide alliance of proteomics and stem cell researchers, which has resulted in the
foundation of an initiative supported by the Human Proteome Organisation (HUPO) and the International Society for Stem Cell
Research (ISSCR) called the Proteome Biology of Stem Cells Initiative. Here we report on the rationale and goals of this initiative.
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Stem cells are an area of biomedical research receiving
broad attention in the scientific literature and in the media
elsewhere. This attention has been inspired by the notion
that human embryonic stem cells have the unique property
to form all cells in the human body, once they receive the
proper signals. The control of this property in vitro would
offer tremendous opportunities to develop treatments of
diseases that cannot be cured today, especially in the area of
regenerative medicine where the aim is to replace damaged
tissue, particularly in organs where capacity for repair is
inherently low (e.g., pancreas, heart, nervous system). The⁎ Corresponding author.
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doi:10.1016/j.scr.2007.08.001approach is of proven value in the clinic, in that hemato-
poietic stem cells offer curative options in a number of
diseases. But there is requirement for other kinds of cell
types for cellular therapies and there is a great deal of
promise that these can be derived from human embryonic
stem cells. Thus, intensive efforts have been and are being
put into multiple approaches aimed at developing stem cell
therapies, from defining standardized culture conditions for
expansion of stem cell lines, to designing and optimizing
strategies for directed differentiation to specific cell
lineages, and, in the long term, to finding ways to implant
cells with the required properties in animals and humans
without challenging the immune system. Apart from these
clinically orientated applications, there is great interest in
using human stem cells and their differentiated derivatives
in drug and toxicology screening. Our understanding of most
of the basic cellular process underlying stem cell self-
renewal, maintenance, and differentiation is still very.
8 A.J.R. Heck et al.limited, and it will be essential to expand our knowledge if
stem cells are also to reach their full potential in this area.
Our increased understanding of hematopoietic stem cell
biology (such as the role of HoxB4 in stem cell expansion) was
derived from basic research programs and offers new options
for deriving populations for cell-based therapies. The same
basic understanding derived from embryonic stem cell
research will similarly support clinical developments. As
such, applying the most advanced systematic techniques to
embryonic stem cell studies is an essential adjunct to current
research approaches.
Proteomics
Proteomics is a technology platform that aims to characterize
proteins in their biological context in a medium- to high-
throughput scenario. This field wasmainly technology-based,
driven initially by the development of mass spectrometers
with the speed and sensitivity amenable to large-scale
analysis of peptides, followed by sophisticated miniaturized
chromatographic systems. Proteomics has more recently
been complemented by an expanding toolbox of bioinfor-
matic applications that have allowed the interpretation of
large sets of mass spectrometric data. As a result, proteomics
today includes a multitude of techniques, such as fractiona-
tion strategies for cell organelles and enrichment steps for
the selective isolation of specific classes of proteins or
peptides (e.g., to identify specific posttranslational modifi-
cations critical in regulating cell fate). Awide variety of mass
spectrometers are now available for the confident identifica-
tion of proteins using either commercial or open source
software tools. The strength of this set of techniques is its
flexibility in being adapted to the biological question that
needs to be addressed. Most importantly, the ability to
relatively or absolutely quantify proteins in different cell
populations allows proteomics to move to a new level. With a
large body of effective technology in place (and more
sensitive instruments in the pipeline), the true challenge
now is to integrate proteomics into the full spectrum of
biological and biomedical research, challenging the creativ-
ity of both the biologist and the analytical chemist and
demanding a dialogue between these research communities.
Proteome biology of stem cells
Considering the many challenges in stem cell biology, there is
a pressing need for the implementation of cutting-edge
approaches such as proteomic applications. This need is
beginning to be realized by a growing number of scientists
who have started to chart the proteome of individual primary
stem cells and stem cell lines and their differentiated
derivatives, to define a subset of stem-cell-specific proteins,
or to identify differentiation-specific proteins that can be
used as benchmarks for the intermediate or terminal steps of
differentiation of cells. Critically, these approaches are also
providing clues to the signal transduction pathways andtranscription factor cascades that drive each differentiation
step. Importantly, recent work on stem cells using proteomics
has shown that transcriptome analyses do not give a full guide
to developmental change in stem cells and protein inter-
actions (which can only be discovered systematically using
proteomic approaches). Thus, certain concepts of processes
regulating development will only be determined by analysis
at the proteome level. However, stem cell biology and
proteomics are both highly specialized scientific domains, so
they are currently rarely united in the work of one person, or
even one lab or one institute. The only way to bridge this gap
and derive optimal benefit fromwhat each field has to offer is
to bring together the specialists from both fields to discuss
needs, possibilities, requirements, and conditions that will
have to be resolved before collaborative efforts can be
successful. This union has been the imperative driving the
launch of the HUPO (see Box 1) initiative Proteome Biology of
Stem Cells. The consortium consists of more than 15 leading
scientists across the globe from both the proteomics and stem
cell communities. From the beginning the initiative has also
been strongly supported by the International Society for Stem
Cell Research (ISSCR), which hosted the inauguration of the
initiative at its annual meeting in Cairns, Australia, in June
2007. Future HUPO and ISSCR meetings will be used as
platforms to further shape the initiative. To this end, joint
HUPO/ISSCR stem cell proteomics sessions have already
been scheduled for the HUPO meetings in Seoul (October
6th – 10th, 2007) and Amsterdam (August 16th – 21st, 2008),
while a dedicated meeting is being considered to bring
together all participants involved. Issues being discussed at
present include short-term goals of an initial, relatively
small-scale collaborative project and possibilities for funding
enabling larger efforts in the longer term. Progress on these
activities, further documentation on the background of the
initiative, and a list of participating groups so far is available
at www.hupo.org/research/stemcells.
Box 1
Human Proteome Organisation (HUPO)
The Human Proteome Organisation (HUPO, www.hupo.
org) is an international scientific organization, launched in
2001, representing and promoting proteomics through
international cooperationby fostering thedevelopmentof
new technologies, techniques, and training. It coordi-
nates the development of standard operating procedures,
and promotes global collaboration in major proteomics
projects by gathering leading international laboratories in
life sciences, bioinformatics, mass spectrometry, and
systemsbiology. Toachieve this,HUPOhas facilitated the
establishment of global consortia in HUPO Initiatives,
each focusing on specific aspects of the development of
proteomic techniques and their application to biologyand
medicine. Over the past few years 9 initiatives have been
launched, ofwhich ProteomeBiologyof StemCells is the
latest addition.
